Zymeworks Inc. (ZYME) is a publicly traded Healthcare sector company. As of July 8, 2026, ZYME trades at $26.06 with a market cap of $1.86B and a P/E ratio of -6.49. ZYME moved +5.53% today. Year to date, ZYME is +0.68%; over the trailing twelve months it is +104.28%. Its 52-week range spans $9.03 to $29.75. Analyst consensus is strong buy with an average price target of $39.00. Rallies surfaces ZYME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GT Biopharma’s AI Push to Advance Multiple NK Cell Engagers by 2027: GT Biopharma has integrated AI-based tools across discovery and engineering of its NK cell engagers, expecting to push multiple candidates into pre-IND development by 2027, intensifying pipeline competition in the antibody-engager space. Zymeworks may face increased pressure to enhance its own platform efficiency and accelerate candidate progression.
| Metric | Value |
|---|---|
| Price | $26.06 |
| Market Cap | $1.86B |
| P/E Ratio | -6.49 |
| EPS | $-4.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.75 |
| 52-Week Low | $9.03 |
| Volume | 432.59K |
| Avg Volume | 0 |
| Revenue (TTM) | $31.62M |
| Net Income | $-236.97M |
| Gross Margin | 0.00% |
10 analysts cover ZYME: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.00.